Effect of lapatinib plus capecitabine (L+C) on quality of life (QOL) compared to capecitabine (C) alone in ErbB2+ metastatic breast cancer (MBC): An exploratory analysis

Authors :: Anthony C. Segreti
David Cella
Charles E. Geyer
David Cameron
Xiaolei Zhou
Mayur M. Amonkar
S. Stein
M. Walker
Source :: Journal of Clinical Oncology. 26:9532-9532
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 9532 Background: In a phase III randomized open-label multicenter trial, L+C improved time to progression and progression free survival vs C alone in women with ErbB2+ MBC who had received prior th...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Time to progression
business.industry
Exploratory analysis
Lapatinib
medicine.disease
Metastatic breast cancer
Capecitabine
Quality of life
Multicenter trial
Internal medicine
medicine
Progression-free survival
skin and connective tissue diseases
business
neoplasms
medicine.drug

Full Text Access

Tools